Microdetermination of parathions by thermo- and ultra-violet decomposition products

By means of the thin layer chromatography (TLC) a study was carried out on the decomposition of methyl parathion, ethyl parathion and sumithion when exposed to heat or ultra-violet irradiation. The results are briefly summarized as follows. 1. Parathions, when exposed to heat, form hydrolysates and such 0-analog as paraoxon as well as S-alky1 isomers. 2. When parathions are exposed to ultra-violet rays at 365 m&#956; and 254 m&#956;, the rate of decomposition is extremely slow. For example, when exposed to such rays in Petri dish for 5 hours, only a small amount of S-alkyl isomer is formed. 3. After heating parathions in a small test tube and conducting TLC, when each 0-analog and S-alkyl isomer above mentioned is confirmed, it is possible to identify a minute amount of each parathion by this method, and thus this method is feasible to apply to practical poison examination as a rapid and simple qualitative examination method.</p

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer

BackgroundThere are no established predictive biomarkers for the effectiveness of first-line atezolizumab plus carboplatin and etoposide therapy in patients with small-cell lung cancer (SCLC). Therefore, the current study aimed to investigate whether the Glasgow prognostic score (GPS), neutrophil-to-lymphocyte ratio (NLR), and body mass index (BMI) can predict the effectiveness of first-line atezolizumab plus carboplatin and etoposide therapy in patients with extensive-disease SCLC.MethodsWe reviewed data from 84 patients who received first-line atezolizumab plus carboplatin and etoposide therapy for SCLC at nine Japanese institutions between August 2019 and May 2021. Further, we evaluated the prognostic value of the GPS, NLR, and BMI. The Kaplan–Meier and Cox proportional hazard models were used to examine differences in progression-free survival (PFS) and overall survival (OS). Moreover, the GPS, NLR, and BMI consisted of C-reactive protein and albumin concentrations, neutrophil and lymphocyte counts, and body weight and height, respectively.ResultsThe response rate was 72.6% (95% confidence interval: 63.0–82.1%). The median PFS and OS from the initiation of treatment were 5.4 (95% CI: 4.9–5.9) months and 15.4 (95% CI: 11.4–16.8) months, respectively. The GPS independently predicted the effectiveness of first-line atezolizumab plus carboplatin and etoposide treatment, as a favorable GPS (GPS 0–1) was correlated with significantly better PFS and OS rates compared to a poor GPS (GPS 2) (PFS: 5.8 vs. 3.8 months, p = 0.0005; OS: 16.5 vs. 8.4 months, p&lt;0.0001).ConclusionsThis is the first analysis to evaluate the association between the GPS, NLR, and BMI and the treatment effectiveness of survival among patients receiving first-line atezolizumab plus carboplatin and etoposide therapy for SCLC. Among patients receiving this treatment for SCLC, GPS was significantly associated with the PFS and OS rates, suggesting that GPS might be useful for evaluating therapeutic outcomes in these patients

Validation of MALDI-TOF MS devices in reanalysis of unidentified pathogenic bacteria detected in blood cultures

In hospital microbial laboratories, morphological and biochemical analyses are performed to identify pathogenic microbes;however, these procedures lack rapidity and accuracy. Recently, Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) has been clinically utilized, and is expected to enable rapid and accurate microbial identification. We aimed to validate two MALDI-TOF MS devices available in Japan: the VITEK-MS (BioMérieux) and the Microflex LT (Bruker Daltonics). Clinically isolated bacteria, 100 samples in all, detected in blood cultures but incompletely identified by conventional procedures, were reanalyzed using the two devices. The VITEK-MS and Microflex LT, respectively, identified 49% (49/100) and 80% (80/100) of the tested bacteria at the species level, as well as 96% (96/100) and 95% (95/100) at the genus level. Among those reidentified strains, 26% (26/100) at the species level and 88% (88/100) at the genus level were concordant with each other, though three strains were unmatched. Moreover, four bacterial strains were unable to be identified using the VITEK-MS, versus five using the Microflex LT. MALDI-TOF MS devices can provide more rapid and accurate bacterial identification than ever before;however, the characteristics of each system were slightly different;therefore, it is necessary to understand the difference in performance of MALDI-TOF MS models

45KDa Estramustine Binding Protein (EMBP) の精製と抗体作成

The purification of 45 KDa EMBP and the production of monospecific anti-serum is described. 45 KDa EMBP was purified by relatively simple methods using ion exchange HPLC (TSK-GEL DEAE-5PW column) and size exclusion HPLC (TSK-GEL G3000SW column). The results clearly demonstrated the speed and simplicity of the method using these columns, compared to previously-described methods for purification of 45 KDa EMBP

Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma

Thymic carcinoma is a rare neoplasm with a dismal prognosis, and there are no established therapeutic regimens for metastatic or recurrent disease. Immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 antibodies, are widely approved in several human cancers, contributing to prolonging survival in thoracic tumors. Thymic carcinoma exhibits histologic properties of squamous cell carcinoma (SQC), and resembles the SQC of the lung. ICIs are not approved in thymic carcinoma. Thus, several clinical trials have been undertaken to demonstrate if they are therapeutically effective for patients with thymic carcinoma. In our review, three prospective phase II studies and several case series were discussed in thymic carcinoma. We found that the objective response rate, disease control rate, and progression-free survival in PD-1 blockade monotherapy were approximately 20%, 73%, and four months, respectively. Two exploratory investigations indicated that PD-L1 within tumor cells exhibits a possibility of the therapeutic prediction of PD-1 blockade in thymic carcinoma. Several case reports, alongside their treatment content, have also been reviewed. The therapeutic efficacy of PD-1 blockade monotherapy is still limited in patients with thymic carcinoma. Future perspectives focus on the therapeutic implication of tyrokinase inhibitors plus ICIs or new experimental agents plus ICIs alongside several ongoing experimental studies

Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma

Thymic carcinoma is a rare neoplasm with a dismal prognosis, and there are no established therapeutic regimens for metastatic or recurrent disease. Immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 antibodies, are widely approved in several human cancers, contributing to prolonging survival in thoracic tumors. Thymic carcinoma exhibits histologic properties of squamous cell carcinoma (SQC), and resembles the SQC of the lung. ICIs are not approved in thymic carcinoma. Thus, several clinical trials have been undertaken to demonstrate if they are therapeutically effective for patients with thymic carcinoma. In our review, three prospective phase II studies and several case series were discussed in thymic carcinoma. We found that the objective response rate, disease control rate, and progression-free survival in PD-1 blockade monotherapy were approximately 20%, 73%, and four months, respectively. Two exploratory investigations indicated that PD-L1 within tumor cells exhibits a possibility of the therapeutic prediction of PD-1 blockade in thymic carcinoma. Several case reports, alongside their treatment content, have also been reviewed. The therapeutic efficacy of PD-1 blockade monotherapy is still limited in patients with thymic carcinoma. Future perspectives focus on the therapeutic implication of tyrokinase inhibitors plus ICIs or new experimental agents plus ICIs alongside several ongoing experimental studies

Advanced Research on Immune Checkpoint Inhibitor Therapy

The human body has an inherent immune surveillance mechanism that eliminates cancer cells and suppresses the development of cancer [...

ラットBBN膀胱腫瘍発生に対する抗腫瘍剤の効果について

F334ラット115匹に0.05%BBNを20週間経口投与し, 同時にADM, CDDP, 生食水の膀胱内注入療法を5週毎に5回連続群(type A, 計20回)週1回群(type B, 計20回)に分け施行した.コントロール群はBBN投与のみとした.40週後に屠殺し検討した.Type Aの生食群はコントロール群におよびtype Bの生食群に比較し有意に膀胱腫瘍重量が増加していた.Type AのADM, CDDP, 膀注群はtype Bの同群より膀胱腫瘍重量が増加していた.ADM, CDDP, 群は2つのtypeでコントロール群に比較し膀胱腫瘍重量の減少した例と増加した例が見られた.組織学的に各群間に差はなかったが, type AのADM群にhigh stage例が多く見られたWe examined the effects of intravesical instillation of adriamycin (ADM) and cis-diammine-dichloroplatinum (CDDP) on the development of bladder tumors induced by 0.05% N-butyl-N-(4-hydroxybutyl)nitrosamine in 115 rats. Intravesical instillation was performed in two ways; continuous administration (5 times a week for 5 weeks) and intermittent administration (once a week). Group 1 (control group) did not receive intravesical instillation. Group 2 I(ADM), group 3 (CDDP) and group 4 (physiological saline) were continuous type. Group 5 (ADM), group 6 (CDDP) and group 7 (physiological saline) received intermittent administration. Bladder weight was significantly higher in group 4 than in groups 1 or 7, and that in groups 2 and 3 than that in group 5 and 6. In groups 2, 3, 5 and 6 bladder weight was almost normal or higher than in the control group, and in group 3 histologically cancer was not seen in one rat. Physiological saline had promoting activity, and ADM and CDDP had both inhibitory and promoting activities. Also, intravesical instillation itself was suggested to promote tumor development under carcinogenic circumstances. We conclude that intermittent intravesical instillation should be performed to inhibit tumor recurrence and intravesical instillation therapy should not be performed clinically for a long period

犬モデルにおけるバルーンレーザーハイパーサーミア(TUBAL-H)後の近位尿道機能の経時的変化

雑種犬6頭のTUBAL-H後の近位尿道機能の変化を評価する為に, 尿道内圧と尿道断面積(CSA, cm2)を同時測定し, これらからコンプライアンス(Comp, cm3/cmH2O)を算出し経時的に検討した.TUBAL-H前にはComp, 最大尿道断面積(MCSA)の平均は, それぞれ0.013, 0.66であった.8週後には, それぞれ0.038, 1.39と増加した.16週後には, それぞれ0.026, 1.21とやや減少した.αブロッカーに対する反応性では, TUBAL-H前ではフェントラミン投与で, Comp, MCSAの平均はそれぞれ0.46, 1.40と増加した.16週後には, フェントラミン投与でCompのみ, 0.033と増加したWe performed transurethral balloon laser hyperthermia of the prostate (TUBAL-H) in 6 mongrel dogs. To evaluate the changes in proximal urethral function after TUBAL-H, the urethral cross sectional area (CSA, cm2) and urethral pressure (Pu, cmH2O) were measured using a balloon probe that allows their simultaneous measurement, and the urethral compliance (Comp, cm3/cmH2O) was calculated from these parameters and serially evaluated. In addition, the changes in Pu, CSA and Comp after administration of an alpha-adrenoceptor antagonist were evaluated before and 16 weeks after TUBAL-H. Before TUBAL-H, the mean Comp was 0.013, and the mean maximum CSA (MCSA) was 0.66. Eight weeks after TUBAL-H, the mean Comp was 0.038, and the mean MCSA was 1.39, showing a significant increase (p < 0.01). Sixteen weeks, after TUBAL-H, the mean Comp was 0.026, and the mean MCSA was 1.21, being lower than those at 8 weeks after TUBAL-H, but significantly higher than those before TUBAL-H (p < 0.05). After administration of the alpha-adrenoceptor antagonist, phentolamine (1 mg/kg), before TUBAL-H, the mean Comp significantly increased to 0.046 (p < 0.05), and the mean MCSA to 1.40 (p < 0.01). The mean Comp was significantly increased to 0.033 (p < 0.05), by phentolamine administration 16 weeks after TUBAL-H, but no other changes were observed. After TUBAL-H, urethral elasticity increased, and this increase persisted for 4 months. The responses of Comp and MCSA to alpha-adrenoceptor antagonist administration before and 16 weeks after TUBAL-H suggested that part of the effects of TUBAL-H is due to damage to alpha-adrenoceptors

Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study

It has been reported that 5.1–7.0% of acute pericarditis are carcinomatous pericarditis. Malignant pericardial effusion (MPE) can progress to cardiac tamponade, which is a life-threatening condition. The effectiveness and feasibility of intrapericardial instillation of carboplatin (CBDCA; 150 mg/body) have never been evaluated in patients with lung cancer, which is the most common cause of MPE. Therefore, we evaluated the effectiveness and feasibility of intrapericardial administration of CBDCA following catheter drainage in patients with lung cancer-associated MPE. In this retrospective study, 21 patients with symptomatic lung cancer-associated MPE, who were administered intrapericardial CBDCA (150 mg/body) at Gunma Prefectural Cancer Center between January 2005 and March 2018, were included. The patients’ characteristics, response to treatment, and toxicity incidence were evaluated. Thirty days after the intrapericardial administration of CBDCA, MPE was controlled in 66.7% of the cases. The median survival period from the day of administration until death or last follow-up was 71 days (range: 10–2435 days). Grade 1–2 pain, nausea, fever, and neutropenia were noted after intrapericardial CBDCA administration. No treatment-related deaths were noted in the current study. Intrapericardial administration of CBDCA (150 mg/body) did not cause serious toxicity, and patients exhibited promising responses to lung cancer-associated MPE. Prospective studies using larger sample sizes are needed to explore the efficacy and safety of this treatment for managing lung cancer-associated MPE